Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 3, 1998, Pages 434-444

  Takeda, Yasuyuki ^a   Kawagoe, Keiichi ^a   Yokomizo, Aki ^a   Yokomizo, Yoshihiro ^a   Hosokami, Toru ^a   Ogihara, Yoshiyasu ^a   Honda, Yuko ^a   Yokohama, Shuichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

DZ 3514; Gastrin cholecystokinin B receptor antagonist; Human cholecystokinin A receptor; Human gastrin cholecystokinin B receptor; Phenoxyacetic acid derivative; Structure activity relationship

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; DZ 3514; GASTRIN ANTAGONIST; L 737415; N METHYL N PHENYL 2 [2 [N (N METHYL N PHENYL CARBAMOYLMETHYL) N [2 [3 (3 METHYLPHENYL)UREIDO]ACETYL]AMINO]PHENOXY]ACETAMIDE; PHENOXYACETIC ACID DERIVATIVE; RP 72540; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG ANTAGONISM; DRUG SYNTHESIS; HORMONE RECEPTOR INTERACTION; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

EID: 0031965829     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.434     Document Type: Article

References (18)

1. Rehfeld J. F., Am. J. Physiol., 240, G255-266 (1981).
2. Innis R. B., Snyder S. H., Proc. Natl. Acad. Sci. U.S.A., 77, 6917-6921 (1980).
3. Hill D. R., Campbell N. J., Shaw T. M., Woodruff G. N., J. Neurosci., 7, 2967-2976 (1987); Hill D. R., Shaw T. M., Woodruff G. N., Neurosci. Lett., 79, 286-298 (1987).
4. Hill D. R., Campbell N. J., Shaw T. M., Woodruff G. N., J. Neurosci., 7, 2967-2976 (1987); Hill D. R., Shaw T. M., Woodruff G. N., Neurosci. Lett., 79, 286-298 (1987).
5. Evans B. E., Bock M. G., Rittle K. E., DiPardo R. M., Whitter W. L., Veber D. F., Anderson P. S., Freidenger R. M., Proc. Natl. Acad. Sci. U.S.A., 83, 4918-4922 (1986).
6. Beinfeld M. C., Neuropeptides, 3, 411-427 (1983).
7. a) Kopin A. S., Lee Y. M., McBride E. M., Miller L. J., Lu M., Lin H. Y., Kolakowski L. F., Jr., Beinborn M., Proc. Natl. Acad. Sci. U.S.A., 89, 3605-3609 (1992);
8. b) Pisegna J. R., Weerth A. D., Huppi K., Wank S. A., Biochem. Biophys. Res. Commun., 189, 296-303 (1992);
9. c) Lee Y. M., Beinborn M., McBride E. M., Lu M., Kolakowski L. F., Jr., Kopin A. S., J. Biol. Chem., 268, 8164-8169 (1993).
10. Bock M. G., Dipardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. F., Anderson P. S., Freidenger R. M., J. Med. Chem., 32, 13-16 (1989).
11. Chang R. S., Lotti V. J., Monaghan J., Birnbaum J., Stapley E. O., Goetz M. A., Schonberg G. A., Patchett A. A., Liesch J. M., Hensens O. D., Springer J. P., Science, 230, 177-179 (1985).
12. Showell G. A., Bourrain S., Neduvelil J. G., Fletcher S. R., Baker R., Watt A. P., Fletcher A. E., Freedman S. B., Kemp J. A., Marshall G. R., Patel S., Smith A. J., Matassa V. G., J. Med. Chem., 37, 719-721 (1994).
13. Satoh M., Kondoh Y., Okamoto Y., Nishida A., Miyata K., Ohta M., Mase T., Murase K., Chem. Pharm. Bull., 43, 2159-2167 (1995).
14. Bertrand P., Bohme G. A., Durieux C., Guyon C., Capet M., Jeantaud B., Boudeau P., Ducos B., Pendley C. E., Martin G. E., Floch A., Doble A., Eur. J. Pharmacol., 262, 233-245 (1994).
15. Ek A., Wiktop B., J. Am. Chem. Soc., 76, 5579-5588 (1954).
16. Bischoff C. A., Chem. Ber., 34, 2125 (1901); Drake N. L., Eaker C. M., Shenk W., J. Am. Chem. Soc., 70, 677-680 (1948).
17. Bischoff C. A., Chem. Ber., 34, 2125 (1901); Drake N. L., Eaker C. M., Shenk W., J. Am. Chem. Soc., 70, 677-680 (1948).
18. Seebach D. Hungerbuhler E., Naef R., Schnurrenberger P., Weidmann B., Zuger M., Synthesis, 1982, 138-141.